NorthStar Asset Management (Pennsylvania)’s Vertex Pharmaceuticals VRTX Stock Holding History

NorthStar Asset Management (Pennsylvania)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$358K	Hold	750	–	–	0.07%	115
2026 Q1	$335K	Hold	750	–	–	0.08%	115
2025 Q4	$340K	Hold	750	–	–	0.07%	119
2025 Q3	$294K	Hold	750	–	–	0.06%	124
2025 Q2	$334K	Hold	750	–	–	0.08%	119
2025 Q1	$364K	Hold	750	–	–	0.09%	115
2024 Q4	$302K	Hold	750	–	–	0.07%	123
2024 Q3	$349K	Hold	750	–	–	0.08%	121
2024 Q2	$352K	Hold	750	–	–	0.09%	115
2024 Q1	$314K	Hold	750	–	–	0.08%	127
2023 Q4	$305K	Hold	750	–	–	0.08%	122
2023 Q3	$261K	Hold	750	–	–	0.08%	128
2023 Q2	$264K	Sell	750 -2	-0.3%	-$674	0.07%	128
2023 Q1	$237K	Buy	752 +2	+0.3%	+$600	0.07%	131
2022 Q4	$217K	Hold	750	–	–	0.07%	133
2022 Q3	$217K	Hold	750	–	–	0.07%	131
2022 Q2	$211K	Buy	+750	New	+$201K	0.07%	129
2020 Q4	–	Sell	-750	Closed	-$204K	–	138
2020 Q3	$204K	Hold	750	–	–	0.07%	123
2020 Q2	$218K	Buy	+750	New	+$203K	0.08%	117

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

NorthStar Asset Management (Pennsylvania)'s VRTX Position: Q2 2026 in Review

NorthStar Asset Management (Pennsylvania) held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 750 shares worth $358K. The position accounts for 0.07% of the portfolio, ranked #115.

NorthStar Asset Management (Pennsylvania) first reported a position in VRTX in Q2 2020 and has held it in 19 quarters since. The position peaked at $364K in Q1 2025. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

NorthStar Asset Management (Pennsylvania) held 750 shares of Vertex Pharmaceuticals worth $358K as of Q2 2026.
NorthStar Asset Management (Pennsylvania) left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.07% of NorthStar Asset Management (Pennsylvania)'s portfolio in Q2 2026, its #115 holding.
NorthStar Asset Management (Pennsylvania) first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
NorthStar Asset Management (Pennsylvania)'s Vertex Pharmaceuticals position peaked at $364K in Q1 2025.
1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on NorthStar Asset Management (Pennsylvania)'s 13F filing for Q2 2026, filed 27 Jul 2026.